For many years, those inside the pharma industry have been telling the same old story about innovation: pharma is big, slow, and risk averse. Start-ups move fast and break things.
Biogen has scaled back its ambitions for Denali-partnered Parkinson’s disease candidate BIIB122, abandoning a complex and likely costly phase 3 trial that isn’t due to com
Health systems globally have reached a critical inflexion point, where ageing populations and tightening budgets mean we can no longer continue to purely treat late-stage symptomatic diseas